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1. Introduction 
Cross-linking is a common method of tissue stabilization. For example, cross-linking is used 
for formaldehyde-induced tissue stiffening and fixation in pathologic specimens. Corneal 
collagen Crosslinking (CXL) is performed with ultraviolet-A (UVA) irradiation at 370 nm 
and the photosensitizer riboflavin (vitamin B2). According to Wollensak (Wollensak, 2006), 
the photosensitizer is excited into its triplet state generating reactive oxygen species (ROS), 
which are mainly singlet oxygen and to a much lesser degree superoxide anion radicals. 
ROS can react further with various molecules inducing chemical covalent bonds that form 
bridges between amino groups of collagen fibrils (type II photochemical reaction). The 
biomechanical effect occurs immediately after irradiation leading to an increase of the 
biomechanical rigidity of the cornea of about 300%. The optimal wavelength of the 
ultraviolet (UV) radiation is 370 nm, at which riboflavin presents maximal absorption. 
Interestingly, a similar mechanism has been detected in the human crystalline lens (Krishna 
et al., 1991). 
2. Corneal collagen cross-linking therapeutic protocol 
All patients who are candidates for CXL treatment need to have maximum keratometric (K) 
readings less than 60 diopters (D) and a central corneal thickness (CCT) of at least 400 μm. 
All clinical trials of CXL refer to patients aged between 18 and 30 years. There are as yet no 
extensive clinical trials in children and this is the reason why great care must be taken when 
applying the CXL technique in patients younger than 18. In addition, patients with a history 
of herpetic keratitis, corneal scarring, severe eye dryness, pregnancy or nursing, previous 
anterior segment surgery, systemic collagen pathology or concomitant autoimmune diseases 
should be handled with great caution and perhaps better excluded. 
In brief, the CXL procedure is conducted under sterile conditions in the operating room, 
after the patient’s eye is anesthetized. According to the Dresden therapeutic protocol, the 
central 8 mm of the corneal epithelium are removed to allow better diffusion of riboflavin 
into the stroma. Without epithelial removal, the biomechanical effect is less than 50% of the 
standard cross-linking procedure. In fact, Botto´s et al. (Botto´s et al., 2008) conclude in their 
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study that treatment of the cornea with riboflavin and UVA without previous de-
epithelialization did not induce any cross-linking effect. Consequently, to facilitate diffusion 
of riboflavin throughout the corneal stroma, the epithelium should be removed as an 
important initial step in the treatment (Botto´s et al., 2008). Partial grid-pattern epithelial 
removal allows some riboflavin penetration, but uptake is limited and non-homogeneous, 
which may affect the efficacy of the cross-linking process (Samaras et al., 2009). Following 
de-epithelialization, a 0.1% riboflavin solution (10 mg riboflavin-5-phosphate in 10 ml 
dextran 20% solution) is instilled to the cornea for 30 min (2 drops every 2 min) prior to the 
irradiation, until the stroma is completely penetrated and the aqueous humour is stained 
yellow. Changes in application time and riboflavin concentration have only little influence 
on stromal depth diffusion (Søndergaard et al., 2010). Generally, the riboflavin film is an 
integral part of the CXL procedure and important in achieving the correct stromal and 
endothelial UVA irradiance (Wollensak et al., 2010). The irradiation is performed from 1 cm 
distance for 30 min using a UVA double diode at 370 nm and an irradiance of 3 mW/cm2 
(equal to a dose of 5.4 J/cm2). The required irradiance is controlled in each patient directly 
before the treatment to avoid a potentially dangerous UVA overdose (Wollensak et al., 
2003a, 2003b). Instillation of riboflavin drops (1 drop every 2 min) is continued during 
irradiation as well, in order to sustain the necessary concentration of riboflavin. Moreover, 
balanced salt solution (BSS) is applied every 6 min to moisten the cornea.  
A series of variations of the treatment protocol have been demonstrated. In 2009 
Kanelopoulos (Kanellopoulos, 2009) demonstrated that CXL by means of a femtosecond 
laser facilitated intrastromal 0.1% riboflavin administration, with promising preliminary 
results. A limited but favourable effect of trans-epithelial CXL was noted on keratoconic 
eyes, without complications by Leccisotti et al. (Lecciotti and Islam, 2010). The effect appears 
to be less pronounced than described in the literature after CXL with de-epithelialization. In 
addition Bakke et al. (Bakke et al., 2009) attempted to compare the severity of postoperative 
pain and the rate of penetration of riboflavin between eyes treated by CXL using excimer 
laser superficial epithelial removal and mechanical full-thickness epithelial removal, and 
concluded that superficial epithelial removal using the excimer laser resulted in more 
postoperative pain and the need for prolonged application of riboflavin to achieve corneal 
saturation.  
3. Laboratory studies 
A series of laboratory studies attempted to explore all aspects of CXL procedure and 
particularly its biomechanical, thermomechanical, and morphological impact on corneal 
cells. A series of observations suggest that the CXL effect is maximal on the anterior part of 
cornea, the collagen fibre diameter is significantly increased only in the anterior half of the 
stroma, in enucleated porcine eyes CXL led to a significant change in the swelling behaviour 
of the anterior stroma (Wollensak et al., 2007a) and significant biomechanical and 
biochemical differences between the anterior and posterior parts were demonstrated in post-
CXL corneas (Kohlhaas et al., 2006; Schilde et al. 2008 ). 
Microcomputer-controlled biomaterial testing experiments indicated an impressive increase 
in corneal rigidity of 71.9% in porcine and 328.9% in human corneas, and an increase in 
Young’s modulus by a factor of 1.8 in porcine and 4.5 in human corneas after CXL. 
Moreover, clinical observations suggest that riboflavin/UVA-induced collagen cross-linking 
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leads to an increase in biomechanical rigidity which remains stable over time (Wollensak 
and Iomdina, 2009; Kling et al., 2010). 
However, the cross-linking effect was maximal only in the anterior 300 μm. The greater 
biomechanical effect in human corneas was attributed to the relatively larger portion of 
crosslinked stroma because of the lower total corneal thickness of 550 μm in human corneas 
compared with 850 μm in porcine corneas (Wollensak et al., 2003c). Also, in a patient with 
acute keratoconus (KC) who underwent CXL, a rapid progress of KC developed 2 years 
after treatment. This was probably due to the fact that CXL does not effectively treat the 
posterior corneal layers and Descemet’s membrane, which are mainly affected by acute KC. 
In normal corneas, the anterior stroma is more rigid because it is designed to maintain the 
anterior corneal curvature. Interestingly, the anterior stroma of these corneas after CXL is 
found to be more cross-linked and still more rigid than the posterior one. This degree of 
rigidity is even preserved in the presence of corneal oedema (Muller et al., 2002). 
In the anterior stroma of rabbit corneas treated with CXL, the collagen fibre diameter was 
significantly increased by 12.2% (3.96 nm), but by only 4.6% (1.63 nm) in the posterior 
stroma (Wollensak et al., 2004c). Similar changes have been reported in the cornea and other 
tissues due to age-related or diabetes mellitus-related collagen cross-linking. A possible 
explanation for this observation is that the induced cross-links push the collagen 
polypeptide chains apart, resulting in increased intermolecular spacing. On scanning 
electron microscopy, the collagen fibres of cross-linked vitreous humour also appeared 
markedly thickened and coarse (Faulborn et al., 1998). 
Experiments in rabbits treated with riboflavin and variable UVA irradiances ranging from 
0.75 to 4 mW/cm2 indicated a variable apoptosis that was proportional to the irradiance 
power. The cytotoxic UVA irradiance level for keratocytes was determined to be about 0.5 
mW/cm2 (Wollensak et al., 2004a). The latter was also confirmed by in vitro studies on 
keratocyte cell cultures (Wollensak et al., 2004b). Cytotoxic apoptosis is followed by 
repopulation approximately after 4–6 weeks from the irradiation (Wollensak at al., 2007b).  
In addition, in cross-linked porcine eyes, a markedly increased resistance to collagenase 
digestion was described, with a 15 day digestion time in the cross-linked samples compared 
with 6 days in the controls (Spoerl et al., 2004). This effect is stronger in the anterior half of 
the cornea. 
4. Corneal collagen cross-linking in keratitis 
Corneal ocular infections may have a profound and devastating impact on visual function. 
Ulcerative keratitis, often microbial in origin and presenting as central or peripheral corneal 
ulceration or infiltration, is a sight-threatening condition. It remains an important cause of 
blindness that requires skilled management and effective chemotherapy to preserve vision 
(Bennett et al., 1998). If diagnosis and initiation of appropriate antimicrobial treatment are 
delayed, it has been estimated that only 50% of eyes will heal with good visual outcome 
(Jones et al., 1981) 
Although the treatment of corneal infections with topical antimicrobial agents has been 
notably successful, with an expanding array of both focused and broad-spectrum antibiotics, 
there has been an alarming resistance to antimicrobial agents (Neu, 1992; DeMuri and 
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Hostetter, 1995; Dever, 1996; Glynn et al., 1998; Levy, 1998). Microbes cleverly develop 
resistance to antibiotics as a result of chromosomal mutation, inductive expression of a 
latent chromosomal genes, or exchange of genetic material via transformation, 
bacteriophage transduction, or plasmid conjugation (Neu, 1992; Bennett et al., 1998). Use of 
the fluoroquinolones in the management of external infections is the most recent example of 
how a new class of antibiotics has been instrumental in changing management strategies for 
the treatment of corneal infections. Also, the antimicrobials currently in use are sometimes 
problematic because of their toxic effects on the ocular surface (e.g., punctate keratitis, 
delayed re-epithelialization, hyperemia, chemosis). Nonetheless, emerging patterns of 
resistance even to these new classes of antimicrobial agents (Daum et al., 1990; Smith et al., 
1990; Thomson et al., 1991; Snyder et al. 1992; Maffett et al. 1993; Chin and Marx, 1994; Fass 
et al., 1995; Knauf et al., 1996; Garg et al., 1999; Goldstein et al., 1999) have stimulated the 
continuing quest for an agent that provides rapid and complete microbicidal activity with 
minimal toxic effects and susceptibility to mechanisms of microbial resistance. 
The antimicrobial activity of UV irradiation includes sporicidal and virucidal effects. 
Traditional applications of UV light are disinfection of drinking water and air/surface 
disinfection. Limitations of the application of UV are mainly the lack of penetration and a 
strong dependence on the distance from the UV source, which may result in non-
homogeneous microbial inactivation. 
On the other hand, riboflavin, or vitamin B2, is a naturally occurring compound and an 
essential human nutrient. Riboflavin products, including lumichrome, are present and 
consumed in a wide range of foods and natural products in common use. Japanese scientists 
demonstrated in the 1960s that riboflavin, when exposed to visible or UV light, could be 
used to inactivate the RNA containing tobacco mosaic virus (Tsugita et al., 1965) Research 
has been developing since 2000 to use riboflavin as a photosensitizer to inactivate pathogens 
in plasma, platelet, and red cell products (Goodrich, 2000). The chemistry, toxicity, and 
ability of riboflavin to interact with nucleic acids after UVA photograph activation have also 
been extensively studied. Riboflavin and UVA (280-370 nm) may damage nucleic acids by 
direct electron transfer, production of singlet oxygen, and generation of hydrogen peroxide 
with formation of hydroxyl radicals. Pathogen DNA/RNA may be affected in the absence of 
oxygen. This process has proven effective against a wide range of pathogens, including 
bacteria, intracellular HIV-1, West Nile virus (WNV), and porcine parvovirus in preclinical 
studies of platelets and plasma. The process also damages leukocyte DNA in a manner that 
makes repair by normal pathways unlikely. There is a possibility that the riboflavin already 
present in the cornea serves as a natural antimicrobial mechanism. However, riboflavin 
concentration in the cornea is not enough to produce antimicrobial effects in overt keratitis. 
Since the riboflavin is photosensitive, it is more likely that the small content of corneal 
riboflavin will be depleted when exposed to sunlight UVA/riboflavin therefore may offer 
high efficacy with low protein damage and little toxicity.  
This development leads to propose that it could act as a photosensitizer useful for the 
inactivation of pathogens found in corneal infections, because of its nucleic acid specificity 
and its limited tendency toward indiscriminate oxidation. Pitts et al. (Pitts et al., 1977) found 
corneal damage at the surface UVA dose (365 mV) of 42.5 J/cm2, and Wollensak et al. 
(Wollensak et al., 2004a) described that riboflavin/UVA treatment leads to dose-dependent 
keratocytes damage in human corneas. The recent clinical use of a riboflavin/UVA 
www.intechopen.com
 
Corneal Collagen Cross-Linking Using Riboflavin and Ultraviolet-A Irradiation in Keratitis Treatment 
 
49 
combination for corneal collagen cross-linking and the observations in the laboratory of 
keratocyte depletion after its application (Wollensak et al., 2003a, 2003b; Labetoulle, 2003; 
Kaufman, 2004) stimulated the evaluation of its application for corneal infection and the 
effort ultimately to expand the armamentarium of antimicrobial agents for the management 
of severe keratitis.  
4.1 Corneal collagen cross-linking in infectious keratitis 
In 2008, Martins et al. (Martins et al., 2008) demonstrated the antimicrobial properties of 
CXL against common pathogens. Some of the microbes used in this study were selected 
from a panel of human clinical ocular isolates from severe cases of bacterial keratitis treated 
at The Wilmer Ophthalmological Institute and maintained by the Microbiology Laboratory, 
Johns Hopkins University School of Medicine. The test panel of human clinical isolates 
maintained by the previously mentioned mcrobiology laboratory included oxacillin-
resistant Staphylococcus epidermidis (ORSE), penicillin-resistant Streptococcus pneumoniae 
(PRSP), and pan-resistant Pseudomonas aeruginosa (PRPA). The other isolates used were 
individual cultures of freeze-dried microorganisms used to assist in the quality control of 
microbiologic media (LyfoCults; PML Microbiologicals, Wilsonville, OR), which included 
ORSE strain (SE), methicillin-resistant Staphylococcus aureus (MRSA), oxacillinsusceptible 
Staphylococcus aureus (SA), and susceptible Pseudomonas aeruginosa (PA). Candida 
albicans (CA) strains were selected from human clinical isolates in the Virology Sector and 
maintained bythe Microbiology Laboratory (Johns Hopkins University School of Medicine). 
Approximately 90% of cases of bacterial keratitis is caused by one of four groups of 
organisms (1): PA (2) SA and Micrococcaceae, (3) SP, and (4) Enterobacteriaceae (Jones, 
1979) Pseudomonas keratitis is one of the most serious corneal infections and represents one 
of the most threatening bacterial infections of the eye. Because of its aggressive behaviour 
and the frequency and context in which it occurs, PA was chosen as a pathogen in this 
study. SA was also used because of its frequency of occurrence as a clinical pathogen. SE is 
an uncommon clinical corneal pathogen; however, its common presence at the ocular 
surface and its occasional conversion to an opportunist led to its selection as a comparison 
test organism. SP is commonly associated with keratitis (3%–15% of cases). 
They tested the riboflavin/UVA combined treatment against two settings of organisms 
based on their antibiotic susceptibility. Group 1 comprised non-resistant organisms: SA, PA, 
and SE. Group 2 was formed by antibiotic-resistant organisms: MRSA, PRPA, PRSP. CA was 
also tested in the same settings. The assay used was a disc diffusion susceptibility test based 
on the principle that a standardized inoculum of the organism is swabbed onto the surface 
of a Mueller-Hinton agar plate, and filter paper discs (Kirby-Bauer discs) impregnated with 
antimicrobial agents are placed on the agar. In this study, the discs were placed in the 
culture plates as reference points, to locate the areas were the riboflavin was previously 
instilled. The discs were also taken as a guide measurement for planimetric assays. 
Riboflavin drops were placed directly adjacent to the discs, to have an area where the light 
exposure would be performed. After 20 minutes of diffusion of the drops in the agar media, 
a beam of UVA light was directed to the selected location for 1 hour, in an attempt to 
photoactivate the vitamin solution or simply to irradiate the area of bacterial growth with 
UVA alone. The experiments were performed three times for each microorganism. After 
UVA irradiation, the agar plates were inverted and incubated for 24 hours at 34°C to 35°C in 
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an ambient-air incubator Digital images of each disc and the surrounding agar area were 
captured (AxioVision software; Axiovert 200M; Carl Zeiss Meditec Inc., Thornwood, NY), to 
measure the area of inhibition zone to the nearest whole millimetre (Herretes et al., 2006). 
The mean growth inhibition zone (GIZ) in square millimeters is inversely proportional to 
the minimum inhibitory concentration (MIC) of the organisms. 
The results in the present study showed significant in vitro inhibition growth of test isolates 
using UVA alone and combined riboflavin/UVA treatment compared with the other types 
of treatment used in the study (B2 alone and B2 previously activated by UVA), for both 
setting of microorganisms. Seemingly, the results also demonstrate that UVA treatment 
alone is less effective in killing test isolates when compared with riboflavin/UVA combined 
treatment in the groups of bacteria tested. Of interest, a very localized response to the area 
of irradiation was observed, with well-defined margins of bactericidal activity, which may 
be particularly useful for corneal application. Riboflavin alone did not seem to have any 
effect as an antibacterial agent, but UVA alone may be effective against all test isolates in 
this study but resistant PA. The combined riboflavin/UVA treatment did not seem to have 
any effect on CA at the riboflavin concentrations tested (0.1% and 0.5%). In the non-resistant 
group, the efficacy of riboflavin/UVA treatment was greater against SA and SE, when 
compared with the treatment applied against PA. In the resistant group, we found the same 
effect, with the treatment being more effective against the Gram-positive microorganisms 
than against PA. Despite those findings, we cannot exclude PA as a potential microorganism 
to be treated with riboflavin/UVA treatment, as it showed some GIZ in both groups. 
In 2010 Sauer et al. (Sauer et al., 2010) demonstrated the antimicrobial properties of 
riboflavin/UVA (365 nm) against fungal pathogens. The antimicrobial properties of 
riboflavin/UVA (365nm), with or without previous treatment with amphotericin B, were 
tested on three groups of fungi selected from severe cases of keratomycosis: Candida albicans, 
Fusarium sp, and Aspergillus fumigatus. They were tested by using Kirby-Bauer discs with 
empty disc (control), riboflavin 0.1% alone (R), UVA alone (UVA), riboflavin 0.1% and 
additional UV-A exposure (R_UVA), amphotericin B alone (A), amphotericin B and 
riboflavin 0.1% (A_R), amphotericin B and UVA (A_UVA), amphotericin B and riboflavin 
0.1%, and additional UVA exposure (A_R_UVA). The mean growth inhibition zone (GIZ) 
was measured around the discs. C. albicans, Fusarium sp, and A. fumigatus did not show any 
increased GIZ after treatment without previous amphotericin B medication. However, GIZ 
was significantly greater after pretreatment with amphotericin B and riboflavin/UVA 
(A_R_UVA) for C. albicans (P=.0005), Fusarium sp (P=.0023) and A. fumigatus (P=.0008) 
compared with A, A_R, and A_UV-A. Amphotericin B is believed to interact with fungi 
membrane sterols to produce aggregates that form transmembrane channels. Given that 
collagen is one of the principal components of the cornea, it is also probable that 
amphotericin B may diffuse easily after cross-linking. Previous treatment with amphotericin 
B allowed riboflavin/UVA effectiveness against C. albicans, Fusarium sp, and A. fumigatus. 
This schema might be used in the future for the treatment of keratomycosis. 
Since these results obtained in vitro do not always correlate with in vivo efficacy, further 
tissue culture models and animal studies are under way to test the efficacy of this treatment 
for infectious keratitis. Iseli et al. (Iseli et al., 2008) evaluated the efficacy of CXL for treating 
infectious melting keratitis. Five patients with infectious keratitis associated with corneal 
melting were treated with CXL when the infection did not respond to systemic and topical 
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antibiotic therapy. Follow-up after cross-linking ranged from 1 to 9 months. In all cases, the 
progression of corneal melting was halted after CXL treatment. Emergency keratoplasty was 
not necessary in any of the five cases presented. Moreover, Micelli-Ferrari et al. (Micelli-
Ferrari et al., 2009) described a case of keratitis caused by the Gram-negative Escherichia coli 
treated with CXL with outstanding outcome. Similar results were also reported by More´n et 
al. (More´n et al., 2010), who treated an infectious keratitis using CXL.  
4.2 Corneal collagen cross-linking in complicated bullous keratopathy with ulcerative 
keratitis 
CXL’s antimicrobial and anti-oedematous properties were demonstrated by (Kozobolis et 
al., 2010) in our report of two patients with combined bullous keratopathy and ulcerative 
keratitis, resistant to conventional treatments. Former investigators suggested that corneal 
cross-linking (CXL) might have beneficial impact against corneal melting from bacterial and 
fungal enzymes, because of the antimicrobial effect of UV-A radiation per se (Spoerl et al., 
2004). Moreover, there is evidence that the post-CXL corneal stabilization might prevent the 
outflow of aqueous humour to the intracorneal space in diseases that manifest with 
endothelial decompensation. Based on the aforementioned hypothesis and evidence, we 
reported our experience with 2 patients with bullous keratopathy and corneal infectious 
keratitis resistant to topical medical treatment who underwent therapeutic CXL. 
The first patient was a 78-year-old woman referred to our department because of 
deteriorating visual acuity (VA) and intense ocular discomfort (pain) in the right eye, 
whereas her left eye was otherwise healthy. Regarding the ophthalmological history, she 
had an extracapsular cataract extraction surgery in her right eye 4 years before her referral. 
According to her medical report, because of high postoperative intraocular pressure, she 
was administered timolol–dorsolamide. fixed combination (twice a day). The systemic 
history revealed diabetes and coronary heart disease. Ophthalmological examination 
revealed the following: A vision-threatening central corneal ulcer accompanied by bullous 
keratopathy (Figure1), which resulted in poor visualization of the anterior chamber 
structures (Figure 2). Despite limited visibility, an anterior chamber intraocular lens could 
be visualized, in situ. Best-corrected visual acuity (BCVA) was limited to light perception, 
whereas corneal thickness (thinnest point) measured by ultrasound pachymetry (Pacline 
Optikon pachymeter, Optikon 2000 SpA; OPTIKON, Rome, Italy) was 641 mm (Table 1). The 
second patient was a 69-year-old man referred to our department because of deteriorating 
VA and intense ocular discomfort (pain) in his left eye, whereas his right eye was otherwise 
healthy. Regarding the ophthalmological history, he had an extracapsular cataract extraction 
surgery in his left eye, 3 years before his referral. Ever since the cataract operation, the 
patient was administered dorsolamide–timolol fixed combination because of postoperative 
ocular hypertension. His systemic history was uneventful. BCVA was 1/20 (Table 1). Slit-
lamp biomicroscopy revealed bullous keratopathy accompanied by infectious keratitis 
(Figure 3). The corneal thickness at the thinnest point was 714 mm (Table 1). Further to 
antiglaucoma medications, both patients were administered intense local antibiotic 
treatment (ofloxacin and tobramycin drops). However, their private physicians reported 
progressive deterioration of the bullous keratopathy and depth of their ulcers. Because of 
the vision-threatening state of their corneas and the poor beneficial effect of local antibiotics, 
CXL was suggested as an experimental but potentially vision-saving adjuvant treatment. 
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The same surgical procedure was applied to both patients, according to the Dresden 
protocol. Prior antibiotic therapy was resumed after the surgical procedure with the 
addition of frequent instillation of artificial tears. Patients’ progress was monitored in a 
daily basis for the first postoperative week for thorough evaluation of the reepithelialization 
process and potential adverse events and then every 15 days for a total of 2-month follow-
up period. 
 
Fig. 1. Preoperative picture (case 1). 
 
Fig. 2. Preoperative anterior chamber optical coherence tomography (case 1). 
 
Fig. 3. Preoperative picture (case 2). 
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Both patients presented a gradual reduction of their corneal edemas associated with 
improved corneal clarity and VA. Moreover, slit-lamp biomicroscopy revealed significant 
improvement of the corneal ulcers (Table 1, Figures 4-7). The reepithelialization was 
completed within a week for both cases. Laboratory analysis of the corneal epithelial smears 
was negative in the first case, whereas in the case 2, Streptococcus viridans was developed. 
BCVA was improved in both cases within the first month after the treatment and remained 
stable during the follow-up period of 2 months. 
 
Table 1. Preoperative and Postoperative VA and Corneal Thickness 
 
Fig. 4. First postoperative day (case 1). 
 
Fig. 5. Final postoperative day (case 1). 
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Fig. 6. First postoperative day (case 2). 
 
Fig. 7. Final postoperative day (case 2). 
Regarding the cases presented above, the induced compactness of the cornea after CXL 
treatment interfered with the outflow of aqueous humor to the intracorneal space because of 
the decompensated endothelium. In fact, the impact of riboflavin and UV radiation on 
endothelial decompensation has been also described by Ehlers et al. (Ehlers et al., 2009). Our 
results confirm their hypothesis because both patients presented a decrease of their corneal 
thickness and disappearance of the corneal bullae. Moreover, the beneficial impact of the 
CXL treatment on corneal edema because of endothelial dysfunction might be inversely 
related to the extent of dysfunction. Thus, maximal therapeutic results are expected in early 
stages of endothelial decompensation. These results attempt to contribute to the body of 
knowledge regarding the potential therapeutic use of CXL with riboflavin in patients with 
bullous keratopathy and corneal infectious keratitis resistant to topical medical treatment 
that would otherwise be treated with penetrating keratoplasty. Obviously, more studies 
are required to explore the potential beneficial impact of the proposed therapeutic 
procedure and provide the necessary data for the development of a valid therapeutic 
protocol. 
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5. Risks and side-effects 
Riboflavin is generally regarded as a safe compound since it is a vitamin ingested in normal 
diets and an omnipresent molecule in biological systems. It is also assumed that any 
residual riboflavin and any photoproducts produced during the treatment do not present 
any hazardous risks. 
On the other hand, UV represents a potential danger to the human eye. It is well known that 
UV-induced photochemical damage, like sunburn or photokeratitis, is caused by UVB light, 
wavelengths of 270 to 315 nm, at power densities ranging from 0.12 to 0.56 J/cm2. In the 
cornea UVB light (290–320 nm) is mainly absorbed by the corneal epithelium (Pitts et al., 
1977; Podskochy, 2004). CXL uses a small peak-like sector of the UVA spectrum (370 nm). 
UVA absorption in the cornea is increased massively during the cross-linking procedure 
due to the photosensitizer riboflavin, resulting in a UVA transmission of only 7% across the 
cornea (Wollensak et al., 2003a). Experiments in rabbits indicated that the cytotoxic level for 
the corneal endothelium was 0.36 mW/cm2. The standard CXL procedure cannot provide 
this cytotoxic level unless the central corneal thickness (CCT) is less than 400 μm (Wollensak 
et al., 2003d, 2003e). In general, UVA is absorbed mainly by the crystalline lens, which also 
contains endogenous riboflavin and other photosensitizers leading to cross-linking of 
crystallines (Krishna et al., 1991). This intrinsic system protects the retina and for this reason 
a UV absorber is usually incorporated into intraocular lenses. For the development of 
cataract, various power values have been reported in the literature at wavelengths between 
290 and 365 nm.(Pitt s et al., 1977; Olsen et al., 1982; Soderberg et al., 2003; Wollensak et al., 
2004a; Kumar et al., 2004; Lin et al., 2004;) With the standard CXL procedure, the lens only 
receives 0.65 J/cm2 which is far below the cataractogenous level of 70 J/cm2 (Pitts et al., 
1977). The retina is damaged by thermal or visible-light–induced photochemical damage in 
the wavelength range of 400–1400 nm. In the rhesus monkey, retinal damage with complete 
loss of the photoreceptor layer was reported at a threshold level of 81 mW/cm2; however, 
such extreme values are incompatible with the standard treatment protocol (Zuclich, 1989). 
On the other hand, after CXL, the stroma is depopulated of keratocytes. HRT II-RCM 
confocal microscopy indicated that the reduction in anterior and intermediate stromal 
keratocytes is followed by gradual repopulation which will be concluded within 6 months. 
The UVA induces oxygen radicals which in turn induce covalent cross-linking of all kinds of 
proteins. The main and almost exclusive protein of the cornea is collagen type I, so that in 
the cornea the effect is focused on collagen. UVA can induce DNA and RNA lesions, an 
effect which is used for the disinfection of water etc. and also for the sterilization of 
aphaeresis blood products, efficiently killing viruses, bacteria and other pathogens. These 
cytotoxic DNA lesions are also the reason for the cytotoxic effect of the treatment on corneal 
keratocytes. As long as the cornea treated has a minimum thickness of 400 μm (as 
recommended), the corneal endothelium will not experience damage, nor will deeper 
structures such as lens and retina. The light source should provide a homogenous 
irradiance, avoiding hot spots (Mazzotta et al., 2007a; 70Spoerl et al., 2007; Avitabile et al., 
1997; Mencucci et al. 2010; Esquenazi et al., 2010). Nevertheless, Mazzotta et al. (Mazzotta et 
al., 2007b) presented two cases, studied through in vivo confocal microscopy, with stage III 
KC that developed stromal haze after the cross-linking treatment, Kymionis et al. (Kymionis 
et al., 2010) reported the development of posterior linear stromal haze after simultaneous 
PRK followed by CXL and Raiskup et al. (Raiskup et al., 2009), after an extensive one-year 
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study of 163 eyes, concluded that advanced KC should be considered at higher risk of haze 
development after CXL due to low corneal thickness and high corneal curvature. In 
addition, Koppen et al. (Koppen et al., 2009) reported four cases of keratitis and corneal 
scarring from a total of 117 eyes treated with CXL and Sharma et al. (Sharma et al., 2010) 
presented a case report of Pseudomonas keratitis after collagen cross-linking for KC. Also, 
Garcia-Delpech et al. (Garcia-Delpech et al., 2010) reposted a case of Fusarium keratitis 3 
weeks after healed corneal cross-linking. Apart from the above-mentioned complications, 
Gokhale et al. (Gokhale and Vemuganti, 2010) presented a case of acute corneal melt with 
perforation in a patient with KC after collagen cross-linking treatment and the use of topical 
diclofenac and proparacaine eyedrops. The use of diclofenac sodium and proparacaine 
eyedrops after surgery was possibly responsible for the corneal melt in this patient, so 
patients who have undergone cross-linking treatment should be observed closely until the 
corneal epithelium heals completely. In addition, a case of advancing KC treated with CXL 
complicated with sterile infiltrates was presented by Mangioris et al. (Mangioris et al., 2010). 
This complication may be an individual hypersensitivity reaction to the riboflavin or UVA 
light in the anterior stroma. At this point we should mention that Goldich et al. (Goldich et 
al., 2010) reported that CXL does not cause damage to the corneal endothelium and central 
retina and Koller et al. (Koller et al. 2009) made a significant effort to evaluate the 
complication rate of CXL for primary keratectasia and to develop recommendations for 
avoiding complications. Their results indicate that changing the inclusion criteria may 
significantly reduce the complications and failures of CXL. A preoperative maximum K 
reading of less than 58 D may reduce the failure rate to less than 3%, and restricting patient 
age to younger than 35 years may reduce the complication rate to 1%. 
6. Conclusion 
CXL is a promising therapeutic intervention for corneal tissue stabilization in diseases that 
manifest with progressive keratectasia, like keratoconus. Moreover, CXL’s anti-oedematous 
and antimicrobial properties have been demonstrated in a series of studies, suggesting its 
therapeutic indications in bullous keratopathy and in infectious keratitis, as an adjuvant 
treatment to conventional therapeutic modalities. These cases show the positive effects of 
CXL with a satisfactory final visual outcome. CXL may be a promising new treatment for 
keratitis, although this remains to be elucidated in detail in future studies. Until more data 
are available this treatment should only be considered in therapy-refractive keratitis or 
ulceration and not in the first line of defence, since it may have cytotoxic side-effects. 
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